The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment

Completed

Conditions: Wilson Disease

Interventions: Drug: Standard of Care Medications

Registration Number: NCT02763215

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Brief Summary: This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications.

After providing informed consent, participants meeting all inclusion and no exclusion criteria were enrolled into the study as outpatients. The participants' routine clinic visits were scheduled according to the standard clinical practice at the study center and at the discretion of the treating physician at approximate 6-month intervals.

At the time of enrollment, participants were receiving SoC medications for the treatment of WD, which could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc. If treatment was interrupted or stopped during the course of the study, participants continued in the study and biological samples and clinical data were continued to be collected for the full 24-month study period. Dosing with SoC agents was individualized and managed by the treating physician at the study center according to standard clinical practice at the site.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 64

Inclusion Criteria

Willing and able to give informed consent for participation in the study.
Male or female participants, aged 18 years or older as of signing the informed consent form.
Receiving SoC medications (penicillamine, trientine, zinc, or copper chelators with zinc) for the treatment of WD at the time of enrollment and for no more than 60 months prior to enrollment.
Able to understand and willing to comply with study procedures and requirements, as judged by the Investigator.
Established diagnosis of WD.
Adequate venous access to allow for collection of blood samples.

Exclusion Criteria

Major systemic disease or other illness that would, in the opinion of the Investigator, compromise participant safety or interfere with the collection or interpretation of study results.
In the opinion of the Investigator, the participant was likely to be non-compliant or uncooperative during the study.

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Total	Standard of Care Medications	-

Primary Outcome Measures

Name	Time	Method
Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of Non-ceruloplasmin-bound Copper (NCC) Or Reached A Reduction Of ≥ 25% In NCC During 6 Months Of Treatment	Baseline through Month 6	To achieve a normalized NCC concentration, participants must have had 2 consecutive measures within (or below) the normal concentration range (0.8 to 2.3 micromolar \[μM\]). Two consecutive measurements required that the measurements occurred on separate dates and were assigned to 2 different visits. Non-ceruloplasmin-bound copper was calculated by subtracting the amount of copper bound to the ceruloplasmin from the total plasma copper concentration.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline In Serum Total Ceruloplasmin (Nephelometry) Used To Calculate NCC At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	The total serum (nephelometry) was measured over time and is reported as milligrams (mg)/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In NCC Concentrations At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	Evaluation of NCC concentrations over time are reported as micromoles/liter (μmol/L). Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Plasma Total Molybdenum At Month 6 And Month 24	Baseline, Month 6, Month 24	The plasma total molybdenum was measured over time and is reported in ng/mL.
Time To Normalization Of NCC If Above The Reference Range At The Time Of Enrollment	Baseline, up to 24 months	The time to normalization of NCC was measured by Kaplan-Meier analysis.
Change From Baseline In 24-Hour Urinary Copper At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	Evaluation of 24-hour urinary copper over time is reported as micrograms (μg)/day. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of NCC Or Reached A Reduction Of ≥ 25% In NCC Through Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	To achieve a normalized NCC concentration, participants must have 2 consecutive measures within (or below) the normal range (0.8 to 2.3 μM). Two consecutive measurements required that the measurements occurred on separate dates and were assigned to 2 different visits. Non-ceruloplasmin-bound copper was calculated by subtracting the amount of copper bound to the ceruloplasmin from the total plasma copper concentration. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Exchangeable Copper At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	The change in exchangeable copper was evaluated over time and is reported as nanograms/milliliter (ng/mL). Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Copper Plasma Ultrafiltrate At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	Change in copper plasma ultrafiltrate was measured over time and is reported as ng/mL. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Plasma Total Copper Used To Calculate NCC At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	Plasma total copper was measured over time and is reported as ng/mL. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Molybdenum Plasma Ultrafiltrate At Month 6 And Month 24	Baseline, Month 6, Month 24	The molybdenum plasma ultrafiltrate was measured over time and is reported as ng/mL.
Change From Baseline In 24-Hour Urinary Molybdenum At Month 6 And Month 24	Baseline, Month 6, Month 24	Evaluation of 24-hour urinary molybdenum over time is reported as μg/day.
Change From Baseline In Hepatic Laboratory Measures For Alanine Aminotransferase (ALT) At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	The ALT levels were measured over time and are reported as units (U)/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Hepatic Laboratory Measures For Aspartate Aminotransferase (AST) At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	The AST levels were measured over time and are reported as U/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Hepatic Laboratory Measures For International Normalized Ratio (INR) At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	The INR was measured over time. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
CGI Scale Item 2 (Global Improvement) At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	The CGI scale item 2 (global improvement) is a rating scale commonly used measure of symptom severity, treatment response, and the efficacy of treatments in treatment studies of participants with mental disorders. It uses the Clinical Global Impression - Improvement Scale (CGI-I), a 7-point scale that requires the Investigator to assess how much the participant's illness has improved or worsened relative to the Baseline state at the beginning of the study and rate as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. A decrease in score indicates improvement in disease severity. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Hepatic Laboratory Measures For Bilirubin At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	Bilirubin was measured over time and is reported as μmol/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).
Change From Baseline In Clinical Global Impression (CGI) Scale Item 1 (Severity Of Illness) At Month 6, Month 24, And Last Assessment	Baseline through Last Assessment (ranging from 1 to 24 months)	The CGI scale item 1 (severity of illness) rating scale is a commonly used measure of symptom severity, treatment response, and the efficacy of treatments in treatment studies of participants with mental disorders. It uses the Clinical Global Impression - Severity Scale (CGI-S), a 7-point scale that requires the Investigator to rate the severity of the participant's illness at the time of assessment, relative to the Investigator's past experience with participants who had the same diagnosis. Considering total clinical experience, a participant was assessed on severity of illness at the time of rating as: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. A decrease in score indicates improvement in disease severity. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).